Biogen Hirulog shows improvement over heparin in patency flow rates in suspected MI -- HERO study.
Executive Summary
BIOGEN's HIRULOG v. HEPARIN SHOWS SIGNIFICANT IMPROVEMENT in the primary endpoint of TIMI-III flow patency in suspected myocardial infarction patients, investigator Harvey White, MD, Green Lane Hospital, New Zealand, reported at the American College of Cardiology annual scientific session in Orlando March 25. The Hirulog Early Reperfusion Occlusion (HERO) trial examined a low dose and a high dose of Hirulog (hirudin) compared to heparin in 412 patients with a suspected MI within the previous 12 hours.